Privia Health Group, Inc. (PRVA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 10/100 (LOW), 41.2 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.33% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- 2 Growth Stocks to Stash and 1 We Turn Down
- Why Privia Health Group (PRVA) Is Getting Attention Now
- Privia Health Group (PRVA) Stock Looks Rich Against Current Earnings
- 1 Cash-Heavy Stock for Long-Term Investors and 2 We Ignore
- The Top 5 Analyst Questions From Privia Health’s Q2 Earnings Call
- Privia Health (PRVA) Q2 2026 Earnings Call Transcript
- Privia Health Group (PRVA) Is Down 5.2% After Raising 2026 Revenue Guidance And Expanding Footprint
- Privia Health Group Q2 Earnings Call Highlights
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Privia Health Group, Inc..
Full PRVA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.